NICE draft guidance recommends apixaban for blood

The National Institute for Health and Care Excellence (NICE) has published a new draft guidance that recommends apixaban (Eliquis) as an option for treating and preventing potentially fatal blood clots. The anti-blood clotting drug apixaban can be used to treat venous thromboembolism (VTE) in adults, which is used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE) Risk factors for VTE include a history of DVT, immobility, active cancer, obesity, hormone replacement therapy or oestrogen containing contraceptive therapy and heart disease. People with suspected DVT or PE are generally treated immediately with drugs that help to prevent the blood